A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

• ClinicalTrials.gov Identifier: NCT00203307
• Recruitment Status: Terminated
• First Posted: September 20, 2005
• Results First Posted: August 10, 2011
• Last Update Posted: August 25, 2011
• Sponsor: Thomas Jefferson University
• Collaborator: Eli Lilly and Company
• Information provided by (Responsible Party): Thomas Jefferson University

Study Description

Brief Summary:

Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study.

The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.

Condition or disease	Intervention/treatment	Phase
Migraine	Drug: Olanzapine during first intervention period and placebo during second intervention period; Drug: Placebo during first intervention period, then olanzapine during second intervention period	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 3 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double
• Primary Purpose: Treatment
• Official Title: A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.
• Study Start Date: May 2004
• Actual Primary Completion Date: March 2006
• Actual Study Completion Date: June 2006

Arms and Interventions

Arm	Intervention/treatment
Olanzapine then Placebo; Olazepam	Drug: Olanzapine during first intervention period and placebo during second intervention period; Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
Placebo then olanzapine	Drug: Placebo during first intervention period, then olanzapine during second intervention period; Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).

Outcome Measures

Primary Outcome Measures :

1. Difference in Migraine Headache Periods During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject. [ Time Frame: 84 day period on placebo compared to 84 day period on olanzapine ]

   Definition of migraine headache period: One migraine period is defined as a 24-hour period starting at the time of onset of the migraine headache, during which the migraine headache is present*.

   Definition of time frames: First treatment period: Day 1 to 84. Second treatment period: day 113-196. Washout phase is day 85-112.

Secondary Outcome Measures :

1. Reduction of Migraine Attack Frequency During Each 28-day Interval of the Active Treatment Period as Compared to Each 28-day Interval of the Placebo Treatment Period, Per Subject. Individual Migraine Attacks Are Separated by 48-hours Pain Free Time. A [ Time Frame: each 28 day interval of active treatment c ompared to placebo ]
2. Reduction in Days Using an Acute Headache Treatment During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject. [ Time Frame: 84 day period on olanzapine compared to 84 day period on placebo ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subjects who are male or female between the ages of 18 and 65, inclusive
• Subjects who have a history of migraine with or without aura as defined by IHS criteria, for at least one year prior to screening
• Subjects who experience between 3 and 10 migraine attacks per month, for the three months preceding screening
• Subjects who have no more than 15 headache days per month
• Subjects who have been on a stable dose (no clinically significant changes) of all daily medications, for any indication, from 28 days prior to screening through the duration of the trial.
• Women who are using, or agree to use for the duration of the study, a medically acceptable form of contraception (as determined by the investigator), if female of childbearing potential.
• Subjects who are able to understand and comply with all study requirements
• Subjects who provide written informed consent prior to any study procedures being performed.

Exclusion Criteria:

• Women who are pregnant or lactating
• Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability (subjects with QTC interval greater than 450ms will be excluded)
• Subjects currently taking, or have taken within the thirty days prior to screening, any neuroleptics > 1 day per week (such as Geodon, Zyprexa, Compazine, Phenergan, Seroquel and other drugs in the same class)
• Subjects currently taking or have taken within 4-weeks prior to screening any medication for the prevention of migraine
• Subjects who have failed more than two adequate trials of migraine prophylaxis, as determined by investigator
• Subjects who experience significant orthostatic hypotension, as determined by the investigator
• Subjects who, in the investigators opinion, have a history or have evidence of a medical condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
• Subjects who, in the investigators opinion, have a history or have evidence of a psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial.
• Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit

Contacts and Locations

Locations

United States, Pennsylvania

Jefferson Headache Center

Philadelphia, Pennsylvania, United States, 19107

Sponsors and Collaborators

Thomas Jefferson University

Eli Lilly and Company

Investigators

• Principal Investigator: Stephen D Silberstein; Thomas Jefferson University

More Information

• Responsible Party: Thomas Jefferson University
• ClinicalTrials.gov Identifier: NCT00203307
• Other Study ID Numbers: SDS/ZYP/02; 080-19000-H55901
• First Posted: September 20, 2005
• Results First Posted: August 10, 2011
• Last Update Posted: August 25, 2011
• Last Verified: August 2011

Additional relevant MeSH terms:

Migraine Disorders; Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Olanzapine; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Gastrointestinal Agents; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Psychotropic Drugs; Serotonin Uptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Serotonin Agents